Fletcher Biosciences is developing a platform for precision immunotherapies that combines proprietary high-throughput protein screening with immune profiling datasets.
What is the problem?
Current immunotherapies cannot precisely target disease-driving immune cells, forcing reliance on broad immune modulation that also disrupts healthy immune function.
What is their solution?
Fletcher Biosciences engineers peptide-MHC (pMHC) biologics that precisely target defined T cell populations. Powered by massively parallel screening systems, this platform enables a new class of precision biologics designed to correct immune dysfunction in autoimmunity, oncology, and infectious disease.
